Evaxion (EVAX) Q4 2025 Earnings Call Transcript

Evaxion reported strong clinical and business progress: EVX-01 Phase II in melanoma delivered a 75% ORR, 25% CRR and 92% of responders maintained response at 2 years, with an 81% neoantigen T‑cell hit rate versus peers reportedly <60%. Merck exercised its option on the EVX‑B3 infectious disease program while declining EVX‑B2 (Evaxion retains global rights), and Evaxion launched an automated AI vaccine design module and a Gates Foundation collaboration for a polio vaccine. Financially, Evaxion received $32M of inflows during 2025, ended the year with $23M cash providing runway into H2 2027, and narrowed net loss to $7.7M; EVX‑04 (AML) aims for a clinical trial application by year‑end 2026. Overall, the combination of validated AI discovery, partnership momentum and improved cash position increases near‑term de‑risking and partnership optionality for the company.

Analysis

Validation from a top-tier pharma partner acts as a de-risking signal to the market but is a double-edged sword: it accelerates clinical and commercial optionality while compressing the upside that accrues to the discovery owner via milestone/royalty economics. Expect more inbound diligence from both large pharmas and philanthropic actors; the immediate second-order winners are CDMOs and assay vendors that can scale bespoke peptide or multi-epitope constructs, which shortens time-to-clinic but raises COGS and supply-chain concentration risks.

The science-to-clinic jump that AI platforms promise hinges on two non-linear transitions: antigen identification -> reproducible immunogenicity across diverse HLA backgrounds, and preclinical immunogenicity -> human efficacy. Both steps carry asymmetric tail risk — systematic model overfitting or manufacturing-driven antigenicity loss would rapidly re-rate the story; conversely, reproducible translational readthrough would re-rate up significantly. Key catalysts are upcoming translational biomarker reads and early regulatory filings over the next 6–18 months; failure or delays here matter materially for valuation.

Consensus is treating the platform as a near-term revenue machine; I’m more cautious. Partner interest is real but often converts into long, milestone-heavy deals rather than near-term cash, meaning upside is binary and timing uncertain. However, the pivot into shared antigens (e.g., ERV-based and infectious-disease targets) is underappreciated: if one shared-antigen program clears early human proof-of-concept, the valuation step-up could be multiple turns because it converts a bespoke service into a scalable product business.

Key Decisions for Investors

• Small asymmetric long in EVAX (12–24 month horizon): allocate ~0.5–1.0% NAV via long-dated call options or a modest outright equity position. Target a 3–5x upside if a Tier-1 partnership or clinical readouts land; hard stop-loss at -50% to cap capital at risk given binary outcomes.
• Event-driven pair: go long EVAX equity and short ~40–60% weight in an unvalidated AI-biotech basket (e.g., equal-weight small-cap biotech ETF exposure via IBB put options) to isolate platform-specific upside while hedging sector volatility. Rebalance around biomarker readouts and regulatory filings over next 6–12 months.
• Directional AI/infra hedge: buy NVDA 9–12 month calls to capture broad AI tailwinds that indirectly support valuation multiples for AI-driven biotechs. Size this as a portfolio hedge (1–2% NAV); if NVDA appreciates, it raises the takeout/partnering bid-ask for platform names.
• Avoid/underweight pure-play incumbent vaccine makers as a hedge to this theme (e.g., GSK) in small size: incumbents may face margin pressure if platform-derived, lower-cost vaccine constructs commoditize early-stage R&D, but they remain defensive — use as tactical hedge rather than core short.
• Trigger-based liquidity plan: if EVAX achieves an early proof-of-concept in a shared-antigen program or signs a multi-hundred-million-dollar deal, take 30–50% profits and reset a trailing-stop to lock gains; if catalyst misses, scale down to zero within 30 days to preserve capital.